Based on synthetic lethality, this innovative approach selectively eliminates cancer cells while sparing normal cells (Minchom et al., 2018), exemplified by the efficacy of ATR inhibitors in ATM-deficient cancers and Wee1 inhibitors in p53-mutant cancers (O’Neil et al., 2017). This evidence concerns the gene ATM and cancer.